BROMAC

Owners

Goods & Services

Anti-bacterial pharmaceuticals; anti-cancer drugs; anti-cancer pharmaceutical preparations; anti-fungal preparations; antiviral pharmaceutical preparations; bacteria removers, namely, antimicrobial preparations for inhibiting the growth of bacteria; biofilm removers, namely, antimicrobial preparations for inhibiting the growth of biofilms; biological preparations for the treatment of cancer and pseudomyxoma peritonei; chemical preparations containing enzymes for pharmaceutical purposes, namely, for the prevention and treatment of cancer and pseudomyxoma peritonei, for inhibiting the growth of bacteria or biofilms, for destroying biofilm infections, or for treating cystic fibrosis, sputum retention, chest infections, respiratory conditions, severe asthma, COPD (chronic obstructive pulmonary disease), ARDS (acute respiratory distress syndrome), pneumonia, fungal infections and haemophilia; chemical preparations for pharmaceutical use, namely, for the prevention and treatment of cancer and pseudomyxoma peritonei, for inhibiting the growth of bacteria or biofilms, for destroying biofilm infections, or for treating cystic fibrosis, sputum retention, chest infections, respiratory conditions, severe asthma, COPD, ARDS, pneumonia, fungal infections and haemophilia; compounds being pharmaceutical preparations for treating cancer; pharmaceutical compositions for the treatment and prevention of cancer and pseudomyxoma peritonei, for inhibiting the growth of bacteria or biofilms, for destroying biofilm infections, or for treating cystic fibrosis, sputum retention, chest infections, respiratory conditions, severe asthma, COPD, ARDS, pneumonia, fungal infections and haemophilia; pharmaceutical preparations for the treatment and prevention of cancer and pseudomyxoma peritonei, for inhibiting the growth of bacteria or biofilms, for destroying biofilm infections, or for treating cystic fibrosis, sputum retention, chest infections, respiratory conditions, severe asthma, COPD, ARDS, pneumonia, fungal infections and haemophilia; pharmaceutical preparations for the treatment of cancer; pharmaceutical products for the prevention and treatment of pseudomyxoma peritonei; pharmaceutical preparations for use in combination therapy for the treatment of cancer and pseudomyxoma peritonei; pharmaceutical preparations for treating glue ear, cystic fibrosis, sputum retention, chest infections, respiratory conditions, haemophilia, myocardial infarction, coronary artery disease, stroke, massive pulmonary embolism, acute limb ischemia, stent-related thrombosis or haemarthrosis; preparations of plants, namely, plant extracts for pharmaceutical use